Key points for the use of bronchodilators

LABAs and LAMAs are preferred over short-acting agents except for patients with only occasional dyspnoea (evidence A)
Patients may be started on single long-acting bronchodilator therapy or dual long-acting bronchodilator therapy. In patients with persistent dyspnoea on one bronchodilator treatment should be escalated to two (evidence A).
Inhaled bronchodilators are recommended over oral bronchodilators (evidence A)
Theophylline is not recommended unless other long-term treatment bronchodilators are unavailable or unaffordable (evidence B)

LABA: long-acting β2-agonist; LAMA: long-acting muscarinic antagonist.